194 related articles for article (PubMed ID: 28951602)
1. Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.
Taguchi A; Hamada K; Hayashi Y
J Antibiot (Tokyo); 2018 Feb; 71(2):205-214. PubMed ID: 28951602
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy].
Shiozuka M; Matsuda R
Brain Nerve; 2011 Nov; 63(11):1253-60. PubMed ID: 22068478
[TBL] [Abstract][Full Text] [Related]
3. Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct.
Taguchi A; Hamada K; Kotake M; Shiozuka M; Nakaminami H; Pillaiyar T; Takayama K; Yakushiji F; Noguchi N; Usui T; Matsuda R; Hayashi Y
ChemMedChem; 2014 Oct; 9(10):2233-7. PubMed ID: 25044534
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Study of Leucyl-3-
Taguchi A; Hamada K; Shiozuka M; Kobayashi M; Murakami S; Takayama K; Taniguchi A; Usui T; Matsuda R; Hayashi Y
ACS Med Chem Lett; 2017 Oct; 8(10):1060-1065. PubMed ID: 29057051
[TBL] [Abstract][Full Text] [Related]
5. New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.
Hamada K; Omura N; Taguchi A; Baradaran-Heravi A; Kotake M; Arai M; Takayama K; Taniguchi A; Roberge M; Hayashi Y
ACS Med Chem Lett; 2019 Oct; 10(10):1450-1456. PubMed ID: 31620232
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics based on stop codon readthrough.
Keeling KM; Xue X; Gunn G; Bedwell DM
Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.
Hamada K; Taguchi A; Kotake M; Aita S; Murakami S; Takayama K; Yakushiji F; Hayashi Y
ACS Med Chem Lett; 2015 Jun; 6(6):689-94. PubMed ID: 26101575
[TBL] [Abstract][Full Text] [Related]
8. 2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases.
Bidou L; Bugaud O; Merer G; Coupet M; Hatin I; Chirkin E; Karri S; Demais S; François P; Cintrat JC; Namy O
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2122004119. PubMed ID: 35994666
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
Lee HL; Dougherty JP
Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
[TBL] [Abstract][Full Text] [Related]
10. [Possible chemotherapy of muscular dystrophy caused by nonsense mutation].
Shiozuka M; Arakawa M; Matsuda R
Rinsho Shinkeigaku; 2004 Nov; 44(11):908-10. PubMed ID: 15651328
[TBL] [Abstract][Full Text] [Related]
11. Development of Conformationally Restricted Negamycin Derivatives for Potent Readthrough Activity.
Omura N; Taguchi A; Kuwahara T; Hamada K; Watanabe M; Nakakuki M; Konno S; Takayama K; Taniguchi A; Nomura T; Shuto S; Hayashi Y
ACS Med Chem Lett; 2023 Dec; 14(12):1807-1814. PubMed ID: 38116427
[TBL] [Abstract][Full Text] [Related]
12. Sense from nonsense: therapies for premature stop codon diseases.
Bidou L; Allamand V; Rousset JP; Namy O
Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
[TBL] [Abstract][Full Text] [Related]
13. Nonsense suppression therapies in human genetic diseases.
Martins-Dias P; Romão L
Cell Mol Life Sci; 2021 May; 78(10):4677-4701. PubMed ID: 33751142
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes.
Allamand V; Bidou L; Arakawa M; Floquet C; Shiozuka M; Paturneau-Jouas M; Gartioux C; Butler-Browne GS; Mouly V; Rousset JP; Matsuda R; Ikeda D; Guicheney P
J Gene Med; 2008 Feb; 10(2):217-24. PubMed ID: 18074402
[TBL] [Abstract][Full Text] [Related]
15. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
[TBL] [Abstract][Full Text] [Related]
16. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
17. Translational readthrough induction of pathogenic nonsense mutations.
Kellermayer R
Eur J Med Genet; 2006; 49(6):445-50. PubMed ID: 16740421
[TBL] [Abstract][Full Text] [Related]
18. Introducing sense into nonsense in treatments of human genetic diseases.
Linde L; Kerem B
Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
[TBL] [Abstract][Full Text] [Related]
19. Serum starvation enhances nonsense mutation readthrough.
Wittenstein A; Caspi M; David Y; Shorer Y; Nadar-Ponniah PT; Rosin-Arbesfeld R
J Mol Med (Berl); 2019 Dec; 97(12):1695-1710. PubMed ID: 31786671
[TBL] [Abstract][Full Text] [Related]
20. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
Nudelman I; Glikin D; Smolkin B; Hainrichson M; Belakhov V; Baasov T
Bioorg Med Chem; 2010 Jun; 18(11):3735-46. PubMed ID: 20409719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
